-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Ocular Therapeutix, Maintains $21 Price Target

Benzinga·12/09/2025 13:17:47
语音播报
Chardan Capital analyst Daniil Gataulin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.